Collaboration with Stakeholders
JPMA is working with various stakeholders to
Joint Statement (2012.07)
JPMA has issued the attached joint statement with the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), the Pharmaceutical Research and Manufacturers of America (PhRMA), and the European Federation of Pharmaceutical Manufacturers and Associations (EFPIA) regarding Internet sales and safe access to medicines.
The IFPMA is joined by The Fondation Chirac, International Council of Nurses (ICN), International Institute of Research Against Counterfeit Medicines (IRACM), Medicines for Malaria Venture, and the European Federation of Pharmaceutical Manufacturers and Associations (EFPIA). Medicines for Malaria Venture (MMV), NCD Alliance, U.S. Pharmacopeial Convention (USP), World Medical Association (WMA) and World Heart Federation. JPMA supports the "Fight the Fakes" campaign in collaboration with the Malaria Venture (MMV), NCD Alliance, U.S. Pharmacopeial Convention (USP), World Medical Association (WMA), and World Heart Federation.
Seminar on Countermeasures against Counterfeit Medicines
On October 24, 2017, the "2017 Countermeasures against Counterfeit Medicines Seminar" was held, attended by 21 JPMA member companies and approximately 60 participants. The seminar was attended by about 60 participants from 21 pharmaceutical association member companies. In response to the Harvoni case in Japan in 2017, the seminar featured presentations from the Ministry of Health, Labour and Welfare's Surveillance Guidance and Narcotics Control Division, Gilead Sciences, Pharmaceutical Security Institute (PSI), LegitScript, Eisai Inc. of the U.S. (Eisai Inc., USA), and other experts in the industry to share and discuss the current status of Countermeasures against Counterfeit Medicines both in Japan and overseas. Details of this seminar are also introduced in the January 2018 issue of JPMA News Letter.
JPMA's participation in the fight against counterfeit medicines and awareness-raising activities in collaboration with the Pharmaceutical Security Institute (PSI)
Thirty-seven pharmaceutical companies from around the world funded the Pharmaceutical Security Institute's (PSI) Countermeasures against Counterfeit Medicines (information gathering, coordination with law enforcement, and awareness-raising activities). JPMA member companies include Astellas Pharma, Chugai Pharmaceutical, Sumitomo Pharma, Eisai, Otsuka Pharmaceutical, and Takeda Pharmaceutical Industries.
Collaboration with Interpol (International Criminal Police Organization)
From 2013 to 2015, 29 global pharmaceutical companies provided financial support to INTERPOL's efforts to combat counterfeit medicines, including awareness-raising activities, detection of counterfeit drug manufacturers and distributors, and capacity building for the detection of counterfeit medicines. Astellas, Chugai, Daiichi Sankyo, Dainippon Sumitomo Pharma, Eisai, Otsuka Pharmaceutical, Shionogi, and Takeda Pharmaceutical Industries participated as members of JPMA.